Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P, Grant S.

Mol Cancer Ther. 2008 Oct;7(10):3285-97. doi: 10.1158/1535-7163.MCT-08-0385.

2.

Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.

Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Giménez MS, Dent P, Grant S.

Mol Cancer Ther. 2007 Feb;6(2):692-702.

3.

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.

Rosato RR, Almenara JA, Maggio SC, Atadja P, Craig R, Vrana J, Dent P, Grant S.

Mol Cancer Ther. 2005 Nov;4(11):1772-85.

4.
5.

Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.

Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S.

Leukemia. 2004 Nov;18(11):1780-8.

PMID:
15385934
6.

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S.

Cancer Res. 2004 Apr 1;64(7):2590-600.

Supplemental Content

Loading ...
Support Center